Atovaquone et proguanil : interactions médicamenteuses

Atovaquone/ proguanil ↓ atovaquone ↓ proguanil Concomitant administration is not recommended. (notice Éfavirenz, lamivudine et ténofovir, Interactions médicamenteuses)

Penicillamine should not be used in patients who are receiving concurrently gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone because these drugs are also associated with similar serious hematologic and renal adverse reactions. (notice Pénicillamine, Précautions)

• Administration with rifampin or rifabutin is known to reduce atovaquone concentrations; concomitant use with MALARONE is not recommended. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Administration with rifampin or rifabutin is known to reduce atovaquone concentrations; concomitant use with MALARONE is not recommended. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

…ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase… (notice Articaïne et adrénaline, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (notice Bupivacaïne, Interactions médicamenteuses)

• Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (notice Bupivacaïne et adrénaline, Interactions médicamenteuses)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Chloroprocaïne, Précautions)

Patients infected with a resistant strain of plasmodia as shown by the fact that normally adequate doses have failed to prevent or cure clinical malaria or parasitemia should be treated with another form of antimalarial therapy. (notice Chloroquine, Mises en garde)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

Antimalarial : artemether/lumefantrine ↓ artemether ↓ dihydroartemisinin ↑ lumefantrine ↔ darunavir The combination of PREZISTA/ritonavir and artemether/lumefantrine can be used without dose adjustments. (notice Darunavir, Interactions médicamenteuses)

Antimalarial: artemether/lumefantrine artemether: effect unknown lumefantrine: effect unknown Monitor for a potential decrease of antimalarial efficacy or potential QT prolongation. (notice Darunavir et cobicistat, Interactions médicamenteuses)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (notice Atovaquone et proguanil, Interactions médicamenteuses)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (notice Dropéridol, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

Antimalarials: Artemether/lumefantrine Atovaquone/ proguanil ↓ artemether * ↓ dihydroartemisinin * ↓ lumefantrine * ↓ atovaquone ↓ proguanil Consider alternatives to artemether/ lumefantrine because of the risk of QT interval prolongation. (notice Éfavirenz, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (notice Étravirine, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (notice Hydroxychloroquine, Interactions médicamenteuses)

Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (notice Lidocaïne et adrénaline, Interactions médicamenteuses)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Lidocaïne et prilocaïne, Interactions médicamenteuses)

Antiparasitic: atovaquone ↓ atovaquone Clinical significance is unknown; however, increase in atovaquone doses may be needed. (notice Lopinavir et ritonavir, Interactions médicamenteuses)

Other Antimalarial Drugs Concomitant administration of mefloquine and other related antimalarial compounds (e.g., quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions (see WARNINGS ). (notice Méfloquine, Interactions médicamenteuses)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Mépivacaïne, Interactions médicamenteuses)

Metoclopramide While antiemetics may be indicated for patients receiving MALARONE, metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available [see Clinical Pharmacology ( 12.3 )] . (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (notice Atovaquone et proguanil, Interactions médicamenteuses)

…ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration… (notice Prilocaïne et adrénaline, Interactions médicamenteuses)

However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim- sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. (notice Pyriméthamine, Interactions médicamenteuses)

…quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol… (notice Rifapentine, Interactions médicamenteuses)

Antiparasitic: atovaquone ↓ atovaquone Clinical significance is unknown; however, increase in atovaquone dose may be needed. (notice Ritonavir, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

…ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be… (notice Ropivacaïne, Interactions médicamenteuses)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (notice Atovaquone et proguanil, Interactions médicamenteuses)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (notice Atovaquone et proguanil, Interactions médicamenteuses)

Pediatric use In antimalarial trials, quinidine was as safe and effective in pediatric patients as in adults. (notice Quinidine, Précautions)

Other antimalarials (e.g., halofantrine, mefloquine). (notice Quinine, Interactions médicamenteuses)